Type 2 Diabetes

W. Timothy Garvey, MD, sits down to discuss the results of SURMOUNT-2, the ongoing revolution of antiobesity medications, and why he is concerned over the growing prevalence of online weight loss clinics

Use of metformin was associated with significant reductions in the risk of developing POAG beyond glycemic control, according to an analysis presented at ADA 2023.

APX3330 showed statistically significant prevention of ≥3-step binocular DRSS worsening compared to placebo, but did not meet the study's primary endpoint.

Data from a pair of phase 2 trials in patients with overweight/obesity and type 2 diabetes presented at ADA 2023 suggest the GIP/GLP-1/Glucagon agonist retatrutide could provide significant weight loss and glycemic control benefits.

Hosts are joined by Cari Berget, RN, MPH, for a deep dive into her efforts to improve the implementation of the latest diabetes technologies in real-world settings through her role as a director of the PANTHER Program.

An analysis presented at ADA 2023 suggests autonomous artificial intelligence testing for diabetic eye diseases promoted health equity across various patient subgroups.

Data from a pair of trials presented at ADA 2023 suggests an upped dose of oral semaglutide could soon be on the horizon, with results supporting use in chronic weight management as well as type 2 diabetes.

Results from the EMPRISE study presented at ADA 2023 showed empagliflozin was associated with a 23% reduction in the risk of diabetic retinopathy progression in adults with T2D.

At ADA 2023, we sat down with W. Timothy Garvey, MD, to learn more about the safety and efficacy of tirzepatide in the SURMOUNT-2 trial and how the results complement SURMOUNT-1.

An analysis at ADA 2023 presents novel findings on the inverse association between clinical and biochemical factors in diabetic retinopathy and age-related macular degeneration.

In an interview at ADA 2023, Aggarwal discusses the efficacy of sotagliflozin on heart failure-related outcomes independent of A1c and the greater implications of these findings.

A new analysis from ADA 2023 suggests positive discordance according to GMI/A1c ratios was associated with an increased risk for diabetic retinopathy.

At ADA 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down with ADCES President-Elect Jane Dickinson, RN, PhD, to discuss her work to address shortfalls of the current language used in the management of diabetes.

Data from a pair of phase 3a trials presented at ADA 2023 provide clinicians with new insight into the effects of once-weekly insulin icodec relative to daily insulin degludec and insulin glargine U100.

At ADA 2023, hosts sit down with Gary Rothenberg, DPM, to discuss awareness and management of diabetic foot ulcers as well as how social determinants of health can influence risk and outcomes for patients with diabetes.

At their annual meeting, the American Diabetes Association debuted updates to their Standards of Care to reflect the approval of teplizumab for delaying the onset of type 1 diabetes and underline the importance of screening for NAFLD in type 2 diabetes.

An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.

According to new data presented at ADA 2023, patients with T2D experience an increased risk of incident retinopathy per 1-SD increase in glycemia risk index.

Data from SURMOUNT-2 presented at ADA 2023 build on results from the SURMOUNT-1 trial, with results detailing the weight loss achieved with tirzepatide in people with type 2 diabetes and overweight or obesity.

A new analysis presented at ADA 2023 suggests a machine learning algorithm may refine the risk of diabetic retinopathy progression and personalize screening intervals for patients.

A pair of phase 2 trials presented at ADA 2023 detail the body weight lowering and glycemic control benefits of orforglipron, an oral GLP-1 RA developed by Eli Lilly and Company.

Research presented at ADA 2023 suggests early glycemic screening in high-risk children may predict future diabetes-related complications, including retinopathy and nephropathy.

A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.

An analysis of data from the NYC A1C Registry suggests women with gestational diabetes were more likely to develop diabetes after giving birth and were also more likely to have difficulty achieving glycemic control after diagnosis.

The FDA's historic June 20, 2023 approval of empagliflozin (Jardiance) and empagliflozin plus metformin hydrochloride (Synjardy) marks the first pediatric type 2 diabetes indication for the SGLT2 inhibitor class and comes less than a year after the debut of DINAMO data.

Based on the results of 2 studies, lower birthweight was associated with younger age, lower prevalence of obesity, and fewer individuals with a family history of T2D.

The investigative team observed a U-shaped relationship between sleep duration and incident diabetes, with the greatest risk when sleep duration was ≥10 hours per day.

Among more than 80,000 older adults with T2D and established CVD, those in the highest quartile of out-of-pocket costs were less likely to initiate a GLP-1 R or SGLT2 inhibitor.

During a presentation at the Metabolic Insitute of America's 7th Heart in Diabetes meeting, Erin Michos, MD, broke down the importance of recognizing the bidirectional risk between diabetes and menopause.

Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.